OncologyOnline.net

Oncology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Thromboembolic events"

Erythropoietin treatment for anemia may reduce the risk for blood transfusions and improve hematologic response in cancer patients, but evidence that the treatment affects survival is inconclusive. ...


Preliminary clinical data was reported at the XXIII Chemotherapy Foundation Symposium in New York, comparing the efficacy and safety of the combination of Thalidomide ( Thalomid ) and Topotecan ( Hyca ...


Two studies found that Raloxifene ( Evista ) and Tamoxifen ( Novaldex ) are both effective in reducing the risk of invasive breast cancer, but each has potential disease and quality of life side effec ...


Treatment with chemotherapy and Avastin ( Bevacizumab ), an anticancer drug, is associated with a greater risk of blood clots in patients’ arteries compared with treatment with chemotherapy only. ...


Echoing recent FDA warnings, a research group from Northern Ireland cautions against over-aggressive use of a group of drugs called "erythropoiesis-stimulating agents" ( ESAs ) to treat anemia in so ...


In patients with high-risk breast cancer, addition of the erythropoiesis-stimulating agent ( ESA ) Epoetin alfa to the chemotherapy regimen may help avoid the decrease in hemoglobin levels and resulti ...


The results from the Phase III REGARD trial of Ramucirumab as a single agent in patients with advanced gastric cancer who have had disease progression after initial chemotherapy were published in The ...


Clinical trials are needed to assess the clinical benefit of antithrombotic prophylaxis in patients with cancer who are receiving chemotherapy, since these patients are at an increased risk of develop ...


A study has compared the incidence of vascular thromboembolic events ( VTEs ) in patients with metastatic or unresectable urothelial carcinoma ( UC ) who were treated with Gemcitabine and Carboplatin ...